Clinical significance of cyclooxygenase-2 and BCRP expressions in non-Hodgkin lymphoma
10.3760/cma.j.issn.1009-9921.2010.08.009
- VernacularTitle:环氧合酶-2和乳腺癌耐药蛋白在非霍奇金淋巴瘤中表达的意义
- Author:
Yongfeng ZHAO
;
Liping SU
;
Meijing ZHENG
;
Jingjing DUAN
- Publication Type:Journal Article
- Keywords:
Lymphoma,non-Hodgkin;
Drug resistance,neoplasms;
Cyclooxygenase 2;
Breast cancer resistance protein
- From:
Journal of Leukemia & Lymphoma
2010;19(8):483-485
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the correlation and significance of cyclooxygenase-2 (COX-2)and the breast cancer resistance protein (BCRP) expressions in non-Hodgkin lymphoma(NHL). Methods Ten patients with reactive lymph nodes (RLN) were considered as a control group. Compared with β-actin as internal control, the BCRP mRNA expressions of 61 NHL samples and 10 lymph tissues in control group were detected by semi-quantitative revere transcription polymerase chain reaction (RT-PCR) assay, while the expressions of COX-2 protein of the above specimens were detected by SP immunohistochemistry. Results The positive rates of COX-2 and BCRP in NHL were 50.8 %(31/61) and 45.8 % (28/61), respectively , and were higher than those in the control group (P ＜0.05). The expression of COX-2 was statistically positive correlated to that of BCRP (X2 =8.795, r=0.355, P＜0.05). The expressions of COX-2 and BCRP were not correlated to clinical and pathological factors, such as age, sex, IPI, LDH, β2-microglobulin level and Ann Arbor stage, however, the expression of BCRP was statistically correlated to chemotherapy efficacy.Conclusion BCRP may be involved in multi-drug resistance (MDR) of NHL, so it may contribute to the assessment of chemotherapy and prediction of NHL. Since there is a strong correlation between COX-2 expression and MDR in NHL, the application of COX-2 inhibitors may enhance sensitivity of chemotherapy.
